Theme: Current Research Advancements and Challenges in the manufacture and production of HIV Vaccines

HIV Vaccines 2016

HIV Vaccines 2016

OMICS International Conferences invites all the participants from all over the world to attend “15th Annual Conference on HIV Vaccines & Therapeutics” which will be held during December 08-09, 2016 in Philadelphia, USA which includes Prompt Keynote presentations, Oral talks, Poster presentations and Exhibitions. The Theme of the conference is "Current Research Advancements and Challenges in the manufacture and production of  HIV Vaccines".

HIV Vaccines 2016 hosting presentations from Global Leaders in the field across the Globe and bringing together vaccine stakeholders including academic researchers, public health clinicians, vaccine policy makers, corporate and vaccine manufacturers. There will be opportunities for those selected to present at the meeting to also publish a manuscripts and abstracts from their talk in the Journal of Vaccines and VaccinationOMICS International organizes 1000+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Track 1: Preventive HIV Vaccines:

Preventive HIV vaccines are designed to protect HIV negative people from becoming infected or getting sick. Although there is currently no vaccine to prevent HIV, researchers are developing and testing potential HIV vaccines. The goal is to develop a vaccine that can protect people from HIV infection, or at least lessen the chance of getting HIV or AIDS should a person be exposed to the virus.

When your body encounters a microorganism, your immune system mounts an attack on the invader. After the microorganism is defeated, your immune system continues to "remember" how to quickly beat the invader should it try to infect you again. A vaccine is designed to resemble a real microorganism. The vaccine trains your immune system to recognize and attack the real microorganism should you ever encounter it. If you've received an effective vaccine, your immune system will "remember" how to quickly attack and defeat a particular microorganism for many years.

Related Conferences:

15th Annual Conference on HIV Vaccines & Therapeutics, December 08-09, 2016 Philadelphia, USA; Vaccines conferences, June 16-18, 2016, Rome, Italy; Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA; 12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE; 11th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA;  HIV Vaccines (X8), USA; HIV Persistence: Pathogenesis and Eradication (X7), USA; American Conference for the Treatment of HIV, USA; The 20th International AIDS Conference, Australia; 2015 National HIV Prevention Conference, USA

Track 2: Therapeutic HIV vaccines:

A therapeutic HIV vaccine (also known as a treatment vaccine) is a vaccine used in the treatment of an HIV infected person. Therapeutic HIV vaccines are designed to boost the body's immune response to HIV in order to better control the infection.

Currently, there are no therapeutic HIV vaccines approved by the Food and Drug Administration (FDA). However, therapeutic HIV vaccines are being tested in clinical trials to find out if they are safe and effective in treating people with HIV. Researchers hope that if therapeutic vaccines are able to strengthen the body's natural anti-HIV immune response, people with HIV will not have to rely exclusively on the antiretroviral drugs now used to treat HIV infection. Currently, anti-retroviral drugs must be taken for life, and some cause serious side effects.

All experimental therapeutic HIV vaccines are in very early stages of research, and no therapeutic vaccine is anticipated to be available to the general public for many years, if at all.

Related Conferences:

11th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA; Annual Conference on  HIV Vaccines & Therapeutics, December 08-09, 2016 Philadelphia, USA; Vaccines conferences, June 16-18, 2016, Rome, Italy; Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA; 12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE; HIV Vaccines (X8), USA; HIV Persistence: Pathogenesis and Eradication (X7), USA; American Conference for the Treatment of HIV, USA; The 20th International AIDS Conference, Australia; 2015 National HIV Prevention Conference, USA

Track 3: Subunit vaccines:

A subunit vaccine presents an antigen to the immune system without introducing viral particles, whole or otherwise. One method of production involves isolation of a specific protein from a virus and administering this by itself.

Instead of the entire microbe, subunit vaccines include only the antigens that best stimulate the immune system. In some cases, these vaccines use epitopes—the very specific parts of the antigen that antibodies or T cells recognize and bind to. Because subunit vaccines contain only the essential antigens and not all the other molecules that make up the microbe, the chances of adverse drug reactions to the vaccine are lower.

Subunit vaccines can contain anywhere from 1 to 20 or more antigens. Of course, identifying which antigens best stimulate the immune system is a tricky, time-consuming process. Once scientists do that, however, they can make subunit vaccines in one of two ways:

  • They can grow the microbes in the laboratory and then use chemicals to break it apart and gather the important antigens.
  • They can manufacture the antigen molecules from the microbe using recombinant DNA technology. Vaccines produced this way are called “recombinant subunit vaccines.”

A recombinant subunit vaccine has been made for the hepatitis B virus. Scientists inserted hepatitis B genes that code for important antigens into common baker’s yeast. The yeast then produced the antigens, which the scientists collected and purified for use in the vaccine. Research is continuing on a recombinant subunit vaccine against hepatitis C virus.

Related Conferences:

Vaccines conferences, June 16-18, 2016, Rome, Italy; Annual Conference on  HIV Vaccines & Therapeutics, December 08-09, 2016 Philadelphia, USA;  Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA; 12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE; 11th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA;  HIV Vaccines (X8), USA; HIV Persistence: Pathogenesis and Eradication (X7), USA; American Conference for the Treatment of HIV, USA; The 20th International AIDS Conference, Australia; 2015 National HIV Prevention Conference, USA

Track 4: Recombinant vector vaccines:

Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.

In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.

Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.

Researchers are working on both bacterial and viral-based recombinant vector vaccines for HIV, rabies, and measles.

Relevant Conferences: 

4th HIV/AIDS, STDs, & STIs Conference, November 30-December 02, 2015, USA; 2nd Infectious Diseases Conference, August 25-27, 2016, USA; 2nd Influenza Conference, September 12-14, 2016, Germany; Infection Prevention and Control Conference, Aug 1-2, 2016, Germany; Annual Conference on  HIV Vaccines, December 08-09, 2016 Philadelphia, USA;  World STI & HIV 2015 Congress, Australia; 19th Annual United States Conference on AIDS, USA; 10th International Workshop on HIV Transmission – Principles of Intervention, USA; 5th Workshop on HCV Therapy Advances – New Antivirals in Clinical Practice, Netherlands; 18th Bangkok International Symposium on HIV Medicine, Thailand

Track 5: DNA vaccines:

DNA vaccination is a technique for protecting an animal against disease by injecting it with genetically engineered DNA so cells directly produce an antigen, resulting in a protective immunological response.

Still in the experimental stages, these vaccines show great promise, and several types are being tested in humans. DNA vaccines take immunization to a new technological level. These vaccines dispense with both the whole organism and its parts and get right down to the essentials: the microbe’s genetic material. In particular, DNA vaccines use the genes that code for those all-important antigens.

Researchers have found that when the genes for a microbe’s antigens are introduced into the body, some cells will take up that DNA. The DNA then instructs those cells to make the antigen molecules. The cells secrete the antigens and display them on their surfaces. In other words, the body’s own cells become vaccine-making factories, creating the antigens necessary to stimulate the immune system.

A DNA vaccine against a microbe would evoke a strong antibody response to the free-floating antigen secreted by cells, and the vaccine also would stimulate a strong cellular response against the microbial antigens displayed on cell surfaces. The DNA vaccine couldn’t cause the disease because it wouldn’t contain the microbe, just copies of a few of its genes. In addition, DNA vaccines are relatively easy and inexpensive to design and produce.

Relevant Conferences:

12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE; Vaccines conferences, June 16-18, 2016, Rome, Italy; 15th Annual Conference on  HIV Vaccines, December 08-09, 2016 Philadelphia, USA;  Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA; 11th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA; 18th Bangkok International Symposium on HIV Medicine, Thailand; HIV Persistence: Pathogenesis and Eradication (X7), USA; American Conference for the Treatment of HIV, USA; The 20th International AIDS Conference, Australia; 2015 National HIV Prevention Conference, USA

Track 6: HIV Vaccines Trials:

Vaccines are evaluated through a series of clearly defined controlled studies to assess these investigational products for safety, immunogenicity and efficacy before they are approved for licensure.  All clinical vaccine trials are bound by international ethical guidelines and, in the case of US trials, Food and Drug Administration (FDA) regulations.

Good Clinical Practice is defined by the International Conferences on Harmonization (ICH) as: “A standard for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial subjects are protected.”

Historically, vaccines have been our best weapon against the world’s deadliest infectious diseases, including smallpox, polio, measles, and yellow fever. Unfortunately, we do not have a vaccine for HIV. The virus has unique ways of evading the immune system, and the human body seems incapable of mounting an effective immune response against it. As a result, scientists do not have a clear picture of what is needed to provide protection against HIV.

Relevant Conferences:

12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE; Vaccines conferences, June 16-18, 2016, Rome, Italy; 15th Annual Conference on  HIV Vaccines, December 08-09, 2016 Philadelphia, USA;  Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA; 11th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA; 18th Bangkok International Symposium on HIV Medicine, Thailand; HIV Persistence: HIV Vaccines (X8), USA; American Conference for the Treatment of HIV, USA; The 20th International AIDS Conference, Australia; 2015 National HIV Prevention Conference, USA

Track 7: Unwanted effects of HIV Vaccines:

If you have HIV (human immunodeficiency virus) or AIDS (acquired immunodeficiency syndrome), you should take special precautions against other infections, such as the flu. That's because you have a disease that makes it difficult for your immune system to fight them. Vaccines (immunizations) can help your body defend itself against infections. However, if you have HIV/AIDS immunizations may effect you differently than people who don't have HIV/AIDS.

Not all vaccines are safe for people with HIV/AIDS. Vaccines made from live viruses should be avoided because they may cause a mild case of the disease. Live vaccines are a weaker form of the germ that causes a particular disease. People with HIV/AIDS should receive vaccines made from inactivated diseases. Inactivated vaccines don't contain a living germ.

Vaccine Side Effects and HIV/AIDS:

Anyone, regardless of their HIV status, is at risk of side effects associated with vaccines, including:

  • Pain, redness, or swelling at the place where you receive the shot
  • Weakness
  • Fatigue
  • Nausea

However, if you have HIV/AIDS, vaccines carry additional risks including:

  • Vaccines may increase your viral load
  • Vaccines may not work as well if your CD4 count is very low. CD4 cells are a type of immune cell. It may help to take strong antiretroviral medications before having a vaccine if your CD4 count is low.
  • Vaccines made from a live virus may cause you to get the disease the vaccine is supposed to prevent.

Relevant Conferences:

15th Annual Conference on  HIV Vaccines, December 08-09, 2016 Philadelphia, USA; Vaccines conferences, June 16-18, 2016, Rome, Italy; Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA; 12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE; 11th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA;  HIV Vaccines (X8), USA; HIV Persistence: Pathogenesis and Eradication (X7), USA; American Conference for the Treatment of HIV, USA; The 20th International AIDS Conference, Australia; 2015 National HIV Prevention Conference, USA

Track 8: Vaccine Administration:

The administration of antigenic material (a vaccine) to stimulate an individual's immune system to develop adaptive immunity to a pathogen. Vaccines can prevent or ameliorate morbidity from infection.

There are two basic types of vaccines: live attenuated and inactivated. The characteristics of live and inactivated vaccines are different, and these characteristics determine how the vaccine is used.

Live attenuated vaccines are produced by modifying a disease-producing (“wild”) virus or bacteria in a laboratory. The resulting vaccine organism retains the ability to replicate (grow) and produce immunity, but usually does not cause illness. Live attenuated vaccines include live viruses and live bacteria.

Inactivated vaccines can be composed of either whole viruses or bacteria, or fractions of either:

  • Fractional vaccines are either protein-based or polysaccharide-based.
  • Protein-based vaccines include toxoids (inactivated bacterial toxin), and subunit or subvirion products.
  • Most polysaccharide-based vaccines are composed of pure cell-wall polysaccharides from bacteria.
  • Conjugate polysaccharide vaccines are those in which the polysaccharide is chemically linked to a protein. This linkage makes the polysaccharide a more potent vaccine.

Relevant Conferences:

15th Annual Conference on  HIV Vaccines, December 08-09, 2016 Philadelphia, USA; Vaccines conferences, June 16-18, 2016, Rome, Italy; Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA; 12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE; 11th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA; The 20th International AIDS Conference, Australia; 2015 National HIV Prevention Conference, USA; 34th Annual Infectious Diseases Conference, USA; XXV International HIV Drug Resistance Workshop, USA; 23rd Conference on Retro-viruses and Opportunistic Infections, USA

Track 9: HIV Vaccines Research:

HIV is a very complex, highly changeable virus, which makes speedy development of successful preventive HIV vaccines very difficult, but not impossible.  It also takes many years to conduct the research, including the careful clinical testing that will lead to a safe and effective vaccine.

Researchers from around the world have been working for more than two decades to create a vaccine that will protect people against HIV infection. NIAID supports the HIV Vaccine Trials Network (HVTN), an international collaboration of scientists and educators searching for an effective and safe HIV vaccine. The U.S. Military HIV Research Program (MHRP) is also engaged in HIV vaccine research and led a large collaboration of clinical scientists also funded by NIAID in implementing a vaccine clinical trial that showed for the first time that an HIV vaccine is possible.

Scientists are continuing to create and test HIV vaccines—in the lab, in animals, and even in human subjects. These vaccine trials help researchers to learn whether a vaccine will work and if it can be safely given to people.

Relevant Conferences:

15th Annual Conference on  HIV Vaccines, December 08-09, 2016 Philadelphia, USA; Vaccines conferences, June 16-18, 2016, Rome, Italy; Annual Conference on H1N1 & Influenza Vaccines, July 25-26, 2016, USA; 12th Global Vaccines & Vaccination Summit and Expo, Oct 20-22, 2016, UAE; 11th Global Summit and Expo on Vaccines & Vaccination, Sept 12-14, 2016, USA; IV Persistence: Pathogenesis and Eradication, USA; American Conference for the Treatment of HIV, USA; 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, USA; 14th European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance- Treatment Strategies & Antiviral Drug Resistance, Italy

 

15th Annual Conference on HIV Vaccines & Therapeutics December 08-09, 2016 Philadelphia, USA

OMICS International Conferences invites all the participants from all over the world to attend "15th Annual Conference on  HIV Vaccines & Therapeutics" during December 08-09, 2016 Philadelphia, USA  which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Following the great success of the 5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, July 27-28, 2015 Brisbane, AustraliaOMICS Group International is organizing the 15th Annual Conference on  HIV Vaccines & Therapeatics which is going to be held in Philadelphia, USA in 2016. This will be the latest in the OMICS group annual vaccine meeting series expecting with 250 Plus Attendees, to provide a forum where key vaccine stakeholders including academic researchers, public health clinicians, veterinarians, vaccine policy makers, and manufacturers can exchange ideas and collaborate. There will be opportunities for those chosen to present at the meeting to publish a manuscript based on their presentation in the Journal of Vaccines & Vaccination or its sister publication, Immunome Research. OMICS International organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend???

With members from around the world focused on learning about Vaccinology/Immunology and its advances; this is your best opportunity to reach the largest assemblage of participants from the Immunology/Vaccinology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new vaccines developments, and receive name recognition at this event. World-renowned speakers, the most recent techniques, developments, and the newest updates in HIV-Immunology/Vaccinology are hallmarks of this conference.

Target Audience:

  • Vaccinology/Immunology Students, Scientists
  • Vaccinology/Immunology Researchers
  • Vaccinology/Immunology Faculty
  • Medical Colleges
  • Vaccinology/Immunology Associations and Societies
  • Business Entrepreneurs
  • Training Institutes
  • Software developing companies
  • Manufacturing Medical Devices Companies
  • Data Management Companies
  • Machinery Manufacturing Companies
  • Others who are related

 

The 15th Annual Conference on HIV Vaccines & Therapeutics to be held at Philadelphia, USA during December 08-09, 2016 hosted by OMICS Group Conferences through the theme "Current Research Advancements and Challenges in the manufacture and production of HIV Vaccines", conference will explore the advances in Vaccines and vaccination. This conference could be an exceptional event that brings along a novel and International mixture of giant and medium cognizance on vaccines and vaccination, leading universities engendering the conference an ideal platform to apportion expertise, foster collaborations across trade and world, and assess elevating technologies across the world. OMICS International Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members and Organizes 300+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies.

Vaccination is a key to eradicate the diseases. It is a subject for the professionals who looks beyond the clinical prospects. Vaccines Asia Pacific-2016 amasses all the extroverts under one roof of current advances.

For more details visit- http://hiv.conferenceseries.com/

      Vaccinology is a major field in eradication of diseases majorly Hiv vaccines need to develop. Traditional approaches to vaccine design were to emasculate or inactivate the human pathogen or a cognate animal homologue, Vaccinology is the science of vaccine development and how the immune system responds to vaccines, but additionally includes perpetual evaluation of immunization programs and vaccine safety and efficacy, as well as surveillance of the epidemiology of vaccine-preventable diseases. This chapter provides a brief overview of some of the main concepts of immunology and vaccinology as they relate to immunization.

Why USA-Philadelphia? 

      In 2015 there are 23 vaccines and related conferences are held in USA. From thar three are from Philadelphia

Philadelphia City Council provides a free immunisation service for children to help protect them against childhood diseases such as measles, whooping cough, polio and tetanus. Providing a free immunisation service is another way Council delivers towards the Atlanta Vision. Around 22 Biological giants are working in USA. Around 15 top universities are working on vaccines research in USA.

Why to attend???

HIV Vaccines-2016 could be an event that brings along a novel and International mixture of giant and medium Vaccinology innovation and incipient trends in vaccines and vaccination, leading universities and vaccinology, vaccination research analysis establishments creating the conference an ideal platform to share expertise, foster collaborations across trade and world, and assess rising technologies across the world. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Vaccinology research are hallmarks of this conference.

A Unique Opportunity for Advertisers and Sponsors at this International event:

http://hiv.conferenceseries.com/

Major Vaccines Associations in & around Miami.

·         Vaccine research Association

·         US vaccination association

·         USA medical association

·         US veterinary association

·         Association of veterinary vaccination

Major Vaccines Associations Globally

·         The International Society for Interferon and Cytokine Research

·         The International Society of Neuroimmunology

·         The International Union of Immunological Societies

·         The Society for Mucosal Immunology

·         The Society for Leukocyte Biology

·         Transplantation Society

·         British Society for Immunology

·         Cell Death Society

·         European Federation of Immunological Societies

·         European Society of Gene Therapy

·         Federation of African Immunological Societies

·         Federation of American Societies for Experimental Biology

·         Federation of Clinical Immunology Societies

·         Immune Deficiency Foundation

·         Infectious Diseases Society of America

Target Audience:

HIV Vaccines-2016 Targets, CEO’s, Directors, Scientists, Professors, Students of all Biotech & Pharma companies, Universities and colleges globally.

Vaccines sales in global leader companies 2012(1st quarter):

·         Pfizer 2.2 B $

·         Sanofi  1.7 B $

·         Merck & Co 1.8 B $

·         GSK 2.5 B $

·         Novartis 0.44 B $

·         EBS 0.88 B $

Companies Associated with Vaccines

 

·         CareDx

·         Atara

·         Biotherapeutics

·         Benitec Limited  

·         InterMune

·         Biotron Limited

·         BioDiem

·         Antisense Therapeutics Limited           

·         GlaxoSmithKline USA Pty Ltd

·         Bionomics

·         USA Pharmaceutical Industries (API)   

·         BioPharmica Limited

Market Analysis of Vaccines

Tripled in value from USD 5B in 2000 to almost USD 24 B in 2013, Global market projected to rise to USD 100 B by 2025. More than 120 new products in the development pipeline. 60 are of importance for developing countries. UNICEF had a market of 1,03 B$ in 2011, PAHO had 400 million dollars in 2011 and total UN market of 340 million dollars in 2002,  1,430 billion dollars in 2011.

 

Overall Statasticks

 

Vaccines Asia Pacific-2015

            Sensing the raising importance of Vaccines, OMICS International hosted the 5th Asiapacific Global Summit and Expo on Vaccines & Vaccination” (Vaccines Asiapacific-2015), scheduled from July 27-29, 2015 in Brisbane, Australia with a theme “Vaccine Research: From Bench to Bedside”.  Benevolent response and active participation was received from the Editorial Board Members of OMICS Group Journals as well as from the Vaccines project managers, Vaccinologists, Immunologists, Vaccine researchers, scientists, doctors, students and leaders from the fields of Vaccines and Vaccination, Immunology, who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

  • Technologies for the Design, Discovery, formulation and administration of vaccines.
  • Developing Next-Gen Conjugate Vaccines.
  • New trends in carbohydrate-based vaccines.
  • Vaccines for Pregnant Women.
  • Recent advances in animal vaccination
  • Adjuvants for human vaccines—current status, problems and future prospects.
  • Current developments in bacterial conjugate vaccines potency.
  • Recent trends in attenuated vaccines.
  • Advancements in vaccine development
  • Vaccination and quality of life
  • Protein subunits- vaccination.
  • Toxoid vaccines and its importance
  • Geriatric Immunization
  • Vaccines under research and development, major diseases
  • Innovative development of vaccines

The conference was embarked with an opening ceremony followed by workshop and a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were;

Dr. Nikolai Petrovsky, Flinders University, Australia

Dr. Roy Hall, The University of Queensland, Australia

Dr. Jan Fohlman, Växjö and Uppsala University, Sweden

Dr. Istvan Toth, The University of Queensland, Australia

Young Researchers:

Towards the development of oral vaccine delivery systems for lipid core peptide-based vaccines using novel multi-layer engineered nanoliposomes against Group A streptococcus

Nirmal Marasini, The University of Queensland, Australia

Title: A Protective Immune Response Using Asymmetric Multi-Epitope Self-Adjuvanting lipopeptide Vaccine Model

Sharareh Eskandari, The University of Queensland, Australia

Title: Binding and immune modulation properties of mannosylated lipo-peptide vaccines

Bita Sedaghat, The University of Queensland, Australia

Title: Liposomes as a Delivery Platform of Vaccines Against Group A Streptoccocus

Khairunnisa Abdul Ghaffar, University of Queensland, Australia

            OMICS International offers its heartfelt appreciation to Societies and Organizations, Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with OMICS International in supporting and making the conference as never before one.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Vaccines Asiapacific-2015, OMICS International is delighted to announce the next event.  Mark your calendars for the upcoming extravaganza," 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination" to be held during October 17-19, 2016 Kuala Lumpur, Malaysia.

Keynote Forum

Tracks

Posters&Accepted Abstracts

 For More details: http://vaccines.global-summit.com/asia-pacific/2015/

 

Vaccines 2014 report

The 4th International Conference on Vaccines & Vaccination, hosted by the OMICS International. It was held in September 24-26, 2014 Valencia, Spain. Generous response and active participation was received from the Editorial Board Members of OMICS International Journals as well as from scientists, researchers and leaders from Pharma, government organizations, students who made this conference as one of most successful and productive events in 2014 from OMICS International. Also, the conference was carried out through various sessions, in which the discussions were held on the following scientific tracks:

Overview

http://www.conferenceseries.com/immunology-conferences.php

• Vaccines and the Basic Immune System

• New Approaches for B and T Cells

• Cellular and Molecular-Based Vaccines

• Vaccines Against Infectious Diseases

• Manufacturing, Production and Development of Vaccines

• Regulatory and Ethical Issues of Vaccines and Public Acceptance

• Current Issues on Clinical Evaluation and Field Trials of Vaccines

• Modern Technologies in Vaccine Discovery and Development

• Age-Specific Immune Response to Vaccination

• Novel Delivery technologies in Vaccines and many more...

The response to 4th International Conference on Vaccines & Vaccination was huge and was attended by about 550 attendees representing 55 countries from different corners of the world. The conference was initiated with a series of invited lectures delivered by both Honorable Guests and members of the keynote forum. The list included

Jeffrey B Ulmer, Novartis Vaccines USA

Ray Spier, Former President, International Society for Vaccines, UK

Michael G Hanna, CEO, Vaccinogen, Inc., USA and many more...

All the above mentioned Honorable Guests and keynote speakers gave their energetic and fruitful contributions at Vaccines-2014.

All accepted abstracts have been indexed in OMICS International -Journal of Vaccines & Vaccination as a special issue. The theme of this Conference was on “Prospects and Development of Prophylactic & Therapeutic Vaccines”. Based on this, speaker’s discussions included many recommendations.

Conference Proceedings

Keynote speakers

Scientific Tracks

Posters

Accepted Abstracts

Sponsors and exhibitors

Sanofi Pasteur SA

U.S. Headquarters, Discovery Drive, Swiftwater, PA 18370

Vaccinogen Inc.,

5300 West view Dr # 406, Frederick, MD 21703, United States

Cellular Technology Limited (CTL)

North & South America

CTL Headquarters, 20521 Chagrin Blvd., Shaker Heights, OH 44122-5350 USA,

Gen Phar

600 Seacoast Pkwy # 100,

Mt Pleasant, SC 29464, United States

 

Vaccines-2013 Report

OMICS International, the global leader in organizing annual “International conferences and Exhibitions on Vaccines and Vaccinations” The Annual Vaccines Conferences provides high-quality, current reports of scientific progress and best practices featured in both invited presentations and submitted oral abstracts and posters. The Global Vaccines Conferences and Expos organized by OMICS International, bring together the diverse disciplines involved in the research and development of vaccines and associated technologies for disease control through immunization. By drawing upon an global audience of CEOs, CSOs, scientists and researchers, healthcare professionals and trainees, veterinarians, vaccine manufacturers, and public health officials, the conference is designed to encourage the exchange of ideas across a broad range of disciplines.

 Highlights of Annual Global Vaccines Conferences-OMICS International

 • Keynote forum

• Exhibitions

• Company Presentations

• Speaker Forum

• Workshops and Symposia’s

• B2B Meetings

• One to One meeting

• Special Session for Students

• Scientific writing

• Journal review

• Grant writing

• Strategies for building a scientific career

• Scientific careers outside of research

• Company Promotions

• Young Research Forum

• Best Poster Awards

• Certification by the “International Organizing committee” and many more... 

 

Vaccines-2012 Report

The 2nd International Conference on Vaccines & Vaccination, hosted by the OMICS International. It was held in August 20-22, 2012 in Hilton Chicago/Northbook, USA. Generous response and active participation was received from the Editorial Board Members of OMICS International Journals as well as from scientists, researchers and leaders from Pharma, government organizations, students who made this conference as one of most successful and productive events in 2012 from OMICS International. Vaccines 2012 hosted 300+ attendees representing 55 countries from different corners of the world. The conference was carried out through various sessions, in which the discussions were held on the following

 Scientific tracks:

• Vaccines and the Basic Immune System

• New Approaches for B and T Cells

• Cellular and Molecular-Based Vaccines

• Vaccines Against Infectious Diseases

• Manufacturing, Production and Development of Vaccines

• Regulatory and Ethical Issues of Vaccines and Public Acceptance

• Current Issues on Clinical Evaluation and Field Trials of Vaccines

• Modern Technologies in Vaccine Discovery and Development

• Age-Specific Immune Response to Vaccination and many more...

 Conference Proceedings

Keynote speakers

Scientific Tracks

Posters

Accepted Abstracts

The response to 2nd International Conference on Vaccines & Vaccination was huge and was attended by about 300 attendies representing 25 countries from different corners of the world. The conference was initiated with a series of invited lectures delivered by both Honorable Guests and members of the keynote forum. The list included

 De-Chu Christopher Vaxin Inc., USA

John Dong GenPhar, USA

Donald E. Greydanus Western Michigan University School of Medicine, USA

Eli Young OpSaniTx, USA

Takashi Kei Kishimoto Selecta Biosciences, USA

Daniel H Zimmerman CEL-SCI Corporation, USA

Gerardo Kaplan FDA, USA

Kei Amemiya U.S. Army Medical Research Institute of Infectious Diseases, USA

Haval Shirwan University of Louisville, USA and many more.

All the above mentioned Honorable Guests and keynote speakers gave their energetic and fruitful contributions at Vaccines-2012.All accepted abstracts have been indexed in OMICS International- Journal of Vaccines & Vaccination as a specialissue. The theme of this Conference was on “Prospects and Development of Prophylactic & Therapeutic Vaccines”. Based on this, speaker’s discussions included many recommendations.

 

 Vaccines-2011 Conference Report

The International Conference and Exhibition on Vaccines & Vaccination (Vaccines-2011) was held on November

22-24, 2011 in Philadelphia Airport Marriott Hotel, USA. This successful conference organized by OMICS Group brought together Medical Specialists, Researchers and Vaccine Developers who were delighted with the many speeches, presentations, and discussions, which demonstrated the determination to innovate and improve knowledge on Vaccines.Vaccines-2011, helped to open new ideas, advanced technologies, innovative approaches towards Vaccines. Several speakers from almost 30 countries have participated in this conference which was carried out through several sessions with the theme “Current Strategies in Vaccination”.

Conference highlighted the following topics:

• Vaccines and the basic immune system

• New approaches for B and T cells

• Cellular and molecular-based vaccines

• Vaccines against infectious diseases

• Therapeutic vaccine manufacturing, production and development

• Logical and ethical issues and vaccines

• Experimental and clinical evaluation of therapeutic vaccines

• Basic Vaccinology and modern vaccine discovery technologies and many more...

The Luxurious accommodation during the conference also created a relaxed and informal atmosphere with

aright setting for highly interactive sessions where the speakers shared the knowledge on current issues and

strategies of Vaccines and Vaccination.

We take an immense pleasure in thanking our Keynote Speakers:

Gary Alan Flory Virginia Department of Environmental Quality, USA

Gregory J. Tobin Biological Mimetics, Inc. (BMI), USA

Kei Amemiya US Army Medical Research Institute, USA

Edmund J. Gosselin Albany Medical College, USA

Mansour Mohamadzadeh University of Florida, USA and many more...

Vaccines 2011 hosted 200+ attendees representing 30 countries from different corners of the world.

 Conference Proceedings

Keynote speakers

Scientific Tracks

Posters

Accepted Abstracts

We are grateful to all speakers, scientific societies, governmental and non-governmental institutions, Professors, scientists, representatives of patient groups from throughout the world for their commitment and the support. We would like to thank our organizing committee members for providing advice on the agenda, and in
Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date December 08-09, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2 Day 3
Poster Opportunity Available

Media Partners

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
hivvaccines@insightconferences.com
Sponsors / Exhibiting / Advertising.
hivvaccines@insightconferences.com
General Queries.
hivvaccines@insightconferences.com

View Proceedings of Previous Conferences

Vaccines Asia Pacific-2015 Proceedings
Vaccines-2014 Proceedings
Vaccines-2013 Proceedings
Vaccines-2012 Proceedings
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.